search
Back to results

Capsule Endoscopy Versus Conservative Therapy for Obscure Gastrointestinal Bleeding

Primary Purpose

Hemorrhage, Anemia

Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Ferrous sulfate
Capsule Endoscopy
Sponsored by
Medical University of South Carolina
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Hemorrhage

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult men and post-menopausal women with iron deficiency anemia and pre-menopausal women with iron deficiency anemia and a negative gynecologic workup or adults with overt GI bleeding as defined by melena or hematochezia with a ≥2 gram drop in hemoglobin after stabilization (Iron deficiency is defined as hemoglobin <13.7 g/dL in men and <12 g/dL in women with serum ferritin level <50 ng/mL). Also, patients with an otherwise unexplained drop in hemoglobin of ≥ 2 g/dL in the setting of hemoccult positive stool
  • Negative EGD and colonoscopy for source of GI bleeding within six months of enrollment into the study.

Exclusion Criteria:

  • Ongoing overt gastrointestinal bleeding requiring ≥4 units of packed RBC's on any given day in the setting of overt bleeding, blood transfusions on separate days (separated by ≥12 hours), or ≥6 units of packed RBC's over the previous 7-day period prior to presentation, in the setting of overt bleeding.
  • Myocardial infarct, acute neurologic event, sepsis, or respiratory failure within the previous 1 week
  • History of small bowel obstruction
  • Pregnant women
  • Prisoners
  • Age less than 18
  • Known GI or hematologic malignancy
  • Achalasia
  • Contraindications to capsule endoscopy (inability to take prep), or felt unsafe to undergo capsule as per study investigators
  • Esophageal stricture that precludes even endoscopic capsule placement
  • History of upper GI or small bowel surgery
  • Inability to take oral iron.
  • Active IV iron use.
  • Alternate source of blood loss (e.g., menorrhagia)
  • Hematemesis sufficient to be the cause of the hemoglobin decline

Sites / Locations

  • Medical University of South Carolina

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Oral Iron

Oral Iron and Capsule Endoscopy

Arm Description

Outcomes

Primary Outcome Measures

Time to first blood transfusion after randomization
Time-to-event analysis. Patients will be provided an index card on which they will record the date of their first blood transfusion after randomization

Secondary Outcome Measures

Total number of blood transfusions
Total number of hospitalizations
Persistent Iron Deficiency Anemia as measured by ferritin and hemoglobin
Total number of bleeding-related procedures performed after randomization
Mortality

Full Information

First Posted
April 4, 2013
Last Updated
June 13, 2018
Sponsor
Medical University of South Carolina
search

1. Study Identification

Unique Protocol Identification Number
NCT01837030
Brief Title
Capsule Endoscopy Versus Conservative Therapy for Obscure Gastrointestinal Bleeding
Official Title
Capsule Endoscopy Versus Conservative Therapy for Obscure Gastrointestinal Bleeding
Study Type
Interventional

2. Study Status

Record Verification Date
June 2018
Overall Recruitment Status
Withdrawn
Why Stopped
not feasible due to funding
Study Start Date
March 2013 (Actual)
Primary Completion Date
March 2013 (Actual)
Study Completion Date
March 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medical University of South Carolina

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes

5. Study Description

Brief Summary
This study is a single center prospective randomized control trial comparing the utility of performing capsule endoscopy compared to conservative management with oral iron therapy as the initial course of action in patients with non-severe obscure occult or obscure overt gastrointestinal (GI) bleeding. The investigators hypothesize that outcomes in patients with non-severe obscure GI bleeding who receive conservative therapy with oral iron will not differ to those on oral iron who undergo capsule endoscopy.
Detailed Description
Although the American Gastroenterological Association suggests that patients with obscure GI bleeding undergo a capsule endoscopy after a negative esophagogastroduodenoscopy (EGD) and colonoscopy, current recommendations from the British Society of Gastroenterology argue that unless there is an inadequate response to iron therapy, further imaging of the small bowel is probably not necessary. Several studies have demonstrated that this approach is reasonably safe. Furthermore, Laine et al demonstrated that when patients with obscure GI bleeding were randomized to either capsule endoscopy or dedicated small bowel contrast radiography, the rates of further bleeding, measured by subsequent hospitalization and blood transfusion events, were similar between the two groups. No study has randomized patients with obscure GI bleeding to receive capsule endoscopy vs. conservative therapy with oral iron. This study is a single center prospective randomized control trial comparing the utility of performing capsule endoscopy compared to conservative management with oral iron therapy as the initial course of action in patients with non-severe obscure occult or obscure overt gastrointestinal bleeding. All patients will be recruited in the G.I. clinic, the endoscopy unit, or during inpatient consults after negative upper endoscopy and colonoscopy. The study will be explained to patients who qualify at that time. During this visit, patients will be questioned with regard to lower or upper G.I. symptoms, including abdominal pain, dyspepsia, nausea, vomiting, weight loss, diarrhea, change in stool character, melena and intermittent hematochezia. All patients will be started on standard dose oral iron therapy after informed consent. If the patient is already taking iron supplements, their dose with be adjusted to the standard regimen after informed consent. Patients will then be randomized to undergo capsule endoscopy or not. For patients randomized to undergo capsule endoscopy, all subsequent evaluation and treatment will be determined by capsule findings (i.e. capsule directed management) and standard of care at our institution. Patients will be followed for 1 year. Follow up lab draws will occur at 1, 3, 6 and 12 months. They will consist of a complete blood count (CBC) and ferritin and can be performed at either the Medical University of South Carolina (MUSC) or an outside facility or office. If performed outside of MUSC, a standard medical records release form will be utilized to obtain the lab information. Patients will be provided with a paper card indicating their date of enrollment in the study. This card will be kept by the patient for the entire 12 month follow up period and will be collected at the end of the follow up period. The card will have an area where the patient can write the date of their first blood transfusion after enrollment. There will also be numerical checkboxes that the patient will check off for each unit of packed red blood cells (RBCs) they receive during the 12 month follow up period. Telephone calls will be made to each patient every 3 months after enrollment to inquire about hospitalizations and bleeding related procedures (including endoscopy, capsule, small bowel radiology, interventional radiology and surgery). Records of these hospitalizations and procedures will be obtained using a standard medical records release form.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hemorrhage, Anemia

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Oral Iron
Arm Type
Other
Arm Title
Oral Iron and Capsule Endoscopy
Arm Type
Other
Intervention Type
Dietary Supplement
Intervention Name(s)
Ferrous sulfate
Intervention Description
Ferrous sulfate 325mg by mouth twice daily for the duration of the 12 month follow up period
Intervention Type
Device
Intervention Name(s)
Capsule Endoscopy
Intervention Description
GIVEN capsule
Primary Outcome Measure Information:
Title
Time to first blood transfusion after randomization
Description
Time-to-event analysis. Patients will be provided an index card on which they will record the date of their first blood transfusion after randomization
Time Frame
12 month follow up period
Secondary Outcome Measure Information:
Title
Total number of blood transfusions
Time Frame
3, 6, 9, and 12 months
Title
Total number of hospitalizations
Time Frame
3, 6, 9, and 12 months
Title
Persistent Iron Deficiency Anemia as measured by ferritin and hemoglobin
Time Frame
1, 3, 6, and 12 months
Title
Total number of bleeding-related procedures performed after randomization
Time Frame
3, 6, 9, and 12 months
Title
Mortality
Time Frame
3, 6, 9, and 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult men and post-menopausal women with iron deficiency anemia and pre-menopausal women with iron deficiency anemia and a negative gynecologic workup or adults with overt GI bleeding as defined by melena or hematochezia with a ≥2 gram drop in hemoglobin after stabilization (Iron deficiency is defined as hemoglobin <13.7 g/dL in men and <12 g/dL in women with serum ferritin level <50 ng/mL). Also, patients with an otherwise unexplained drop in hemoglobin of ≥ 2 g/dL in the setting of hemoccult positive stool Negative EGD and colonoscopy for source of GI bleeding within six months of enrollment into the study. Exclusion Criteria: Ongoing overt gastrointestinal bleeding requiring ≥4 units of packed RBC's on any given day in the setting of overt bleeding, blood transfusions on separate days (separated by ≥12 hours), or ≥6 units of packed RBC's over the previous 7-day period prior to presentation, in the setting of overt bleeding. Myocardial infarct, acute neurologic event, sepsis, or respiratory failure within the previous 1 week History of small bowel obstruction Pregnant women Prisoners Age less than 18 Known GI or hematologic malignancy Achalasia Contraindications to capsule endoscopy (inability to take prep), or felt unsafe to undergo capsule as per study investigators Esophageal stricture that precludes even endoscopic capsule placement History of upper GI or small bowel surgery Inability to take oral iron. Active IV iron use. Alternate source of blood loss (e.g., menorrhagia) Hematemesis sufficient to be the cause of the hemoglobin decline
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrew Brock, MD
Organizational Affiliation
Medical University of South Carolina
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical University of South Carolina
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
21561874
Citation
Goddard AF, James MW, McIntyre AS, Scott BB; British Society of Gastroenterology. Guidelines for the management of iron deficiency anaemia. Gut. 2011 Oct;60(10):1309-16. doi: 10.1136/gut.2010.228874. Epub 2011 May 11.
Results Reference
background
PubMed Identifier
8633576
Citation
Gordon S, Bensen S, Smith R. Long-term follow-up of older patients with iron deficiency anemia after a negative GI evaluation. Am J Gastroenterol. 1996 May;91(5):885-9.
Results Reference
background
PubMed Identifier
19282769
Citation
McLoughlin MT, Tham TC. Long-term follow-up of patients with iron deficiency anaemia after a negative gastrointestinal evaluation. Eur J Gastroenterol Hepatol. 2009 Aug;21(8):872-6. doi: 10.1097/MEG.0b013e328321836c.
Results Reference
background
PubMed Identifier
20138043
Citation
Laine L, Sahota A, Shah A. Does capsule endoscopy improve outcomes in obscure gastrointestinal bleeding? Randomized trial versus dedicated small bowel radiography. Gastroenterology. 2010 May;138(5):1673-1680.e1; quiz e11-2. doi: 10.1053/j.gastro.2010.01.047. Epub 2010 Feb 2.
Results Reference
background

Learn more about this trial

Capsule Endoscopy Versus Conservative Therapy for Obscure Gastrointestinal Bleeding

We'll reach out to this number within 24 hrs